← Leaderboards
Eugene D. Kwon
Loyola University Chicago
$5,382,460
Attributed
$6,138,914
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2005–14$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
Funding mix
By agency
NIH$6,138,914 · 4
By mechanism
R01$3,634,398 · 3
P30$2,504,516 · 1
Top collaborators
- Haidong Dong6 shared
Most similar at Loyola University Chicago
Same institution · by research overlap
- Katherine L Knight$21,243,692
- Isabelle Caroline Le Poole$8,988,921
- Lydia L Doncarlos$2,803,805
- Elizabeth J Kovacs$23,448,857
Others in their field
Top investigators on “Cellular Immunity”
- Lawrence Corey · Fred Hutchinson Cancer Center$362,792,246
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$302,377,251
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$232,589,547
- Barton F Haynes · Duke University$105,397,476
- Dan H. Barouch · Fred Hutchinson Cancer Center$98,474,803
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$81,038,836
Research focus
Cellular ImmunityCellsImmunotherapyLigandsLinkCancer PatientMalignant Neoplasm Of ProstateImmunotherapeutic AgentMediatingMaleTumorAntigensOrganImmunityAndrogensAreaMolecularBaseT LymphocyteNeoplasm /Cancer ImmunotherapyT-LymphocyteLaboratory MouseImmune ResponseHormone Regulation /Control Mechanism
Grant awards (21)
Clinical Impact of B7-H Immune Cell Coregulators in Renal Cell Carcinoma$268,069
R01 · FY2014 · CA · contact PI
Program Leadership$467,508
P30 · FY2013 · CA · contact PI
Clinical Impact of B7-H Immune Cell Coregulators in Renal Cell Carcinoma$285,880
R01 · FY2013 · CA · contact PI
Program Leadership$406,649
P30 · FY2012 · CA · contact PI
Clinical Impact of B7-H Immune Cell Coregulators in Renal Cell Carcinoma$304,127
R01 · FY2012 · CA · contact PI
Program Leadership$510,114
P30 · FY2011 · CA · contact PI
Clinical Impact of B7-H Immune Cell Coregulators in Renal Cell Carcinoma$27,767
R01 · FY2011 · CA · contact PI
Program Leadership$555,432
P30 · FY2010 · CA · contact PI
Clinical Impact of B7-H Immune Cell Coregulators in Renal Cell Carcinoma$313,533
R01 · FY2010 · CA · contact PI
Program Leadership$564,813
P30 · FY2009 · CA · contact PI
Clinical Impact of B7-H Immune Cell Coregulators in Renal Cell Carcinoma$313,533
R01 · FY2009 · CA · contact PI
Lowering T Cell Thresholds for Tumor Immunotherapy$268,171
R01 · FY2009 · CA · contact PI
Lowering T Cell Thresholds for Tumor Immunotherapy$268,171
R01 · FY2008 · CA · contact PI
Lowering T Cell Thresholds for Tumor Immunotherapy$37,073
R01 · FY2007 · CA · contact PI
Lowering T Cell Thresholds for Tumor Immunotherapy$295,270
R01 · FY2006 · CA · contact PI
Lowering T Cell Thresholds for Tumor Immunotherapy$302,375
R01 · FY2005 · CA
Lowering T Cell Thresholds for Tumor Immunotherapy$302,375
R01 · FY2004 · CA
CTLA-4 BLOCKADE IMMUNOTHERAPY FOR PROSTATE CANCER$137,240
R01 · FY2002 · CA
CTLA-4 BLOCKADE IMMUNOTHERAPY FOR PROSTATE CANCER$85,194
R01 · FY2002 · CA
CTLA-4 BLOCKADE IMMUNOTHERAPY FOR PROSTATE CANCER$215,956
R01 · FY2001 · CA
CTLA-4 BLOCKADE IMMUNOTHERAPY FOR PROSTATE CANCER$209,664
R01 · FY2000 · CA